The new state-of-the-art plant will expand Sanofi’s manufacturing capacity in Vietnam to meet the fast growing demand of the Vietnamese pharmaceutical market and will serve as an export platform to ASEAN (Association of South East Asian Nations ) countries.

The investment in this new plant will amount to USD 75 million and will constitute Sanofi’s largest investment in Vietnam to date. With an initial capacity of 90 million units per year - and a possible extension up to 150 million units - the facility will produce high-quality pharmaceuticals and consumer healthcare products. The plant is scheduled to be fully operational by the end of 2015 and will join Sanofi’s existing network of 40 manufacturing sites in Emerging Markets.

“This new production and development center is the largest investment ever made by Sanofi in Vietnam and illustrates our commitment to bringing high quality medicines to a broader population in Vietnam”, said Christopher A. Viehbacher, chief executive officer of Sanofi. “Sanofi has been present in Vietnam for more than 50 years and has built the number 1 position in one of the most dynamic South East Asian countries. This new investment will contribute to further strengthen Sanofi’s leadership position in Emerging Markets”.

Sanofi Vietnam head office is located in Ho Chi Minh City. Its products have been present in Vietnam for more than 50 years. The company currently has about 1,200 employees working nationwide. Sanofi is the only foreign pharmaceutical company with two WHO-GMP certified manufacturing facilities in Ho Chi Minh City, manufacturing 80 per cent of the volume of Sanofi products marketed in Vietnam. - March 30, 2013